NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$58.98 +0.11 (+0.19 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$58.87
Today's Range$58.20 - $59.05
52-Week Range$39.07 - $60.92
Volume617,100 shs
Average Volume826,606 shs
Market Capitalization$8.11 billion
P/E Ratio737.25
Dividend YieldN/A
Beta2.28
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$507.67 million
Cash Flow$0.3537 per share
Book Value$3.36 per share

Profitability

Net Income$-5,960,000.00

Miscellaneous

Employees547
Market Cap$8.11 billion
OptionableOptionable

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its earnings results on Tuesday, August, 7th. The company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.20. The firm had revenue of $117.75 million for the quarter, compared to analysts' expectations of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Ionis Pharmaceuticals.

How can I listen to Ionis Pharmaceuticals' earnings call?

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, February 27th at 11:30 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for IONS?

7 brokerages have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $46.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $53.7143 in the next twelve months. This suggests that the stock has a possible downside of 8.9%. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News stories about IONS stock have been trending neutral this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO & Sr. VP of Translational Medicine (Age 58)
  • Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 57)
  • Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.36%), BB Biotech AG (6.35%), BlackRock Inc. (5.58%), First Trust Advisors LP (1.61%), Geode Capital Management LLC (0.98%) and Pinnacle Associates Ltd. (0.66%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Pinnacle Associates Ltd., Tocqueville Asset Management L.P., Millennium Management LLC, Los Angeles Capital Management & Equity Research Inc., Raymond James & Associates, Stifel Financial Corp and California Public Employees Retirement System. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, D. E. Shaw & Co. Inc., BlackRock Inc., Two Sigma Investments LP, First Trust Advisors LP, Geode Capital Management LLC, BB Biotech AG and Bellevue Group AG. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $58.98.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $8.11 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  499 (Vote Outperform)
Underperform Votes:  519 (Vote Underperform)
Total Votes:  1,018
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel